S. P. Travis, M. Czajkowski, D. P. McGovern, R. G. Watson and A. L. Bell, “Treatment of Intestinal Behcet’s Syndrome with Chimeric Tumour Necrosis Factor Alpha Antibody,” Gut, Vol. 49, No. 5, 2001, pp. 725-728. doi:10.1136/gut.49.5.725

has been cited by the following article:

• TITLE: Efficacy of Infliximab Therapy for a Patient with Superficial Thrombophlebitis and Rheumatoid Arthritis

  AUTHORS: Masahiro Tada, Kazuyoshi Fukai, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Hiroaki Nakamura, Tatsuya Koike

  KEYWORDS: Infliximab, Superficial Thrombophlebitis, Treatment, Rheumatoid Arthritis, Tumor Necrosis Factor α

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.4, September 30, 2011

  ABSTRACT: Superficial thrombophlebitis is known as a frequent complication of Behçet’s disease. Infliximab may promote healing of superficial thrombophlebitis in patients with Behçet’s disease. However, thrombophlebitis as a complication of rheumatoid arthritis (RA) is rare and treatments have not been reported. We describe the case of a 47-year-old man with RA with complications of superficial thrombophlebitis who was treated using methotrexate and infliximab. Erythema nodosum and cord-like induration with pain in the extremities completely disappeared following a single infusion of infliximab and oral acetylsalicylic acid was not needed. This case suggests that infliximab might offer effective treatment for patients showing superficial thrombophlebitis with RA.